Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present Novozymes A/S (OTC: NVZMY).

Full DD Report for NVZMY

Recent News from (OTC: NVZMY)

Novozymes (NVZMY) Investor Presentation - Slideshow
The following slide deck was published by Novozymes A/S ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 14 2018 15:21
Novozymes A/S ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Novozymes A/S ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: February, 08 2018 13:23
My Commentaries On Recent U.S. Market And Value Picks In Europe
Last month, I wrote the following articles on Seeking Alpha, explaining why the US stock market was seeing its largest bubble in history as well as advising on protection against possible bear market and recession: The Warren Buffett Indicator Is Now Telling You Not To Bet On America My...
Source: SeekingAlpha
Date: February, 07 2018 12:55
Novozymes A/S ADR reports Q4 results
Novozymes A/S ADR ( OTCPK:NVZMY ): Q4 EPS of DKK2.69 Revenue of DKK3.67B (-1.1% Y/Y) Press Release More news on: Novozymes A/S ADR, Earnings news and commentary,
Source: SeekingAlpha
Date: February, 07 2018 11:50
Bioceres Proposes Terms For $130 Million IPO
Quick Take Bioceres ( BIOX ) intends to raise $130 million in a U.S. and Argentine IPO of its ordinary shares and ADSs. The firm sells genetically modified [GM] agricultural products such as seeds, seed traits, biologicals, seed treatments and fertilizers. BIOX has been busy acquir...
Source: SeekingAlpha
Date: January, 26 2018 14:08
Novozymes A/S ADR 2016 Q4 - Results - Earnings Call Slides
The following slide deck was published by Novozymes A/S ADR in conjunction with their 2016 Q4 earnings Read more ...
Source: SeekingAlpha
Date: January, 19 2017 14:43
Enzyme Leader Novozymes: Biotech Without Biotech Risk
Introduction Novozymes ([[NVZMY]]/CPH: NZYM-B), founded in 1925 and headquartered in Denmark, is the largest producer and seller of industrial enzymes globally. The global industrial enzyme market size is estimated to be DKK 25 billion or USD 3.8 billion in 2015, of which Novozymes command...
Source: SeekingAlpha
Date: July, 04 2016 12:03
Bayer buyout of Monsanto "relatively unlikely," analyst says
A Monsanto ( MON +4.9% ) takeover by Bayer is considered " relatively unlikely " by Jefferies analyst Laurence Alexander, as he expects MON to object to the offer given its conviction in its R&D pipeline and longer-term competitive advantages. More news on: Monsanto Company, Syngenta...
Source: SeekingAlpha
Date: May, 19 2016 11:48
The Global X FTSE Nordic Region ETF: The Perfect Fit
European economies get a lot of undeserved bad press. Take the European Union for instance. A few of its economies are indeed lagging like Portugal and Greece, but at the same time several are excelling like the United Kingdom and Germany. The same may be said for the core Eurozone economy. Th...
Source: SeekingAlpha
Date: December, 07 2015 18:01
Novo Nordisk: Is This Your Rainy Day Fund? I Think So!
Novo Nordisk (NYSE: NVO ) is a large Danish insulin manufacturer and one of the most influential players in the obesity/diabetes market. The firm has satisfied investors for decades. It's been one of my favorite firms of all time and in this article I will discuss why. As shown underneath in...
Source: SeekingAlpha
Date: November, 16 2015 11:10


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Novozymes A/S (OTC: NVZMY)

Logo for Novozymes A/S (OTC: NVZMY)

Novozymes is the biotech based world leader in enzymes and microorganisms. With more than types of enzymes and microorganisms and not less than different products Novozymes has the largest product portfolio in the world. lt br / gt In more than different industries and countries, our biological solutions improve industrial performance and quality while at the same time saving on water, energy, raw materials and waste. Novozymes is quoted on the Copenhagen Stock Exchange.


Contact Information



Current Management

  • Steen Riisgaard / President, CEO
  • Thomas Steenbech Bonhoff / Head of IR

Current Share Structure

  • Market Cap: $2,859,584,969 - 03/09/2018
  • Issue and Outstanding: 54,251,280 - 07/21/2011


Recent Filings from (OTC: NVZMY)

Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017


Daily Technical Chart for (OTC: NVZMY)

Daily Technical Chart for (OTC: NVZMY)

Stay tuned for daily updates and more on (OTC: NVZMY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NVZMY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVZMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of NVZMY and does not buy, sell, or trade any shares of NVZMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: